{"id":"W4388495440","doi":"10.1136/ijgc-2023-igcs.2","title":"PO002/#156  Efficacy and safety results from skyscraper-04: an open-label randomized phase 2 trial of tiragolumab plus atezolizumab for PD-L1-positive recurrent cervical cancer","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Clinical endpoint; TIGIT; Randomized controlled trial; Regimen; Progression-free survival; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001883243,0.001623303,0.002262936,0.0004442286,0.000494611,0.001351045,0.001005025,0.001983966,0.01573044],"category_scores_gemma":[0.001521353,0.0007186051,0.002280982,0.0003468554,0.001495858,0.001455545,0.0003904207,0.00427207,0.003207677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007546286,"about_ca_system_score_gemma":0.001296602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006184139,"about_ca_topic_score_gemma":0.001513298,"domain_scores_codex":[0.9993649,0.0003244553,0.0000365155,0.0001050501,0.00005831834,0.0001106654],"domain_scores_gemma":[0.9992467,0.0002099623,0.0001546638,0.00007306099,0.00005605671,0.0002595143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9338718,0.01350994,0.0008160379,0.0007691043,0.001347053,0.00006172803,0.00005529424,0.0006175014,0.008095458,0.0002154814,0.003879454,0.03676124],"study_design_scores_gemma":[0.8948086,0.1000405,0.002039129,0.00002255155,0.000456052,0.00004332804,0.00002461261,0.0004749308,0.0007326188,0.0001440757,0.001193243,0.00002043296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783025,0.003654589,0.000904274,0.001810378,0.00070425,0.004073961,0.004021741,0.0003745601,0.006153757],"genre_scores_gemma":[0.9744477,0.002149272,0.00268736,0.002290177,0.0005964158,0.004176961,0.004300417,0.00009753428,0.009254104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01573044,"threshold_uncertainty_score":0.05262357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08152142274293853,"score_gpt":0.4260592654103299,"score_spread":0.3445378426673914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}